MDY Mdy Healthcare

RNS No 3791e
MEDISYS PLC
6th August 1997



MEDISYS PLC
("Medisys" or "the Company")

Submission of Premarket Approval application to
United States Food and Drug Administration ("FDA")


Medisys,  the medical systems designer and manufacturer  which
was admitted to AIM on 28 July 1997, announces that
it has filed a Premarket Approval ("PMA") application with the
FDA  for  the NiC1800, its innovative system designed for  the
disposal of used hypodermic needles.

The  filing was submitted yesterday by Wilson Sonsini Goodrich
& Rosati, the Company's regulatory legal counsel in the United
States, following completion of clinical trials and laboratory
testing in accordance with FDA requirements.

Medisys  expects  the  FDA review process  will  be  completed
before  the  end  of the year. FDA approval  will  enable  the
Company  to  introduce  the NiC1800  into  the  United  States
market.

The  NiC1800,  which  is the subject of  a  number  of  patent
applications,  is  capable of instantly destroying  hypodermic
needles at point of use.

The  system is marketed to healthcare institutions and private
practitioners  as  a cost-effective way of disposing  of  used
needles  and  reducing  the incidence of needlestick  injuries
among healthcare workers.

It was estimated in 1995 that there were more than one million
needlestick  injuries  in  the United  States  alone  in  1994
creating   a   multi-billion  dollar  problem  for  healthcare
providers.   On  the basis of figures contained  in  a  recent
report  by  the National Audit Commission on the cost  of  NHS
medical waste disposal, Medisys estimates the NiC1800 can save
the  user  more than twenty per cent of annual needle disposal
costs.

The  NiC1800  is  currently being sold in the United  Kingdom,
Europe, Asia and Mexico.

Commenting  on the submission, Michael Coy, Managing  Director
of Medisys, said:

"Approximately twelve billion hypodermic needles are  produced
annually.   Any  one of these is potentially a  carrier  of  a
debilitating  or even deadly disease.  In the  United  States,
the  FDA  is charged with regulating matters affecting  public
health.  The FDA has agreed to a review of the PMA application
and  a  response is expected within 90 days. We  believe
that  this reflects the concern in the United States with  the
growth in the incidence of blood-borne pathogens, such as  HIV
and Hepatitis B."


For further information please contact:

Medisys:
Michael Coy        0171 436 3353

Binns & Company:
Peter Binns        0171 786 9600


END

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jul 2023 bis Jul 2024